Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cel-Sci Corp (CVM)

Cel-Sci Corp (CVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cel-Sci Corp 8229 BOONE BLVD. SUITE 802 VIENNA VA 22182 USA

www.cel-sci.com P: 703-506-9460

Description:

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies.

Key Statistics

Overview:

Market Capitalization, $K 46,573
Enterprise Value, $K 42,423
Shares Outstanding, K 63,807
Annual Sales, $ 0 K
Annual Net Income, $ -32,190 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -6,860 K
EBIT, $ -27,710 K
EBITDA, $ -23,750 K
60-Month Beta 0.59
% of Insider Shareholders 16.24%
% of Institutional Shareholders 12.08%
Float, K 53,445
% Float 83.76%
Short Volume Ratio 0.44

Growth:

1-Year Return -73.17%
3-Year Return -91.28%
5-Year Return -91.49%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 60.96%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.14 on 08/14/24
Next Earnings Date 12/27/24 [--]
Earnings Per Share ttm -0.58
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 26.32%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 06/15/17

CVM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -239.31%
Return-on-Assets % -102.69%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 4.90
Book Value/Share 0.16
Interest Coverage -46.34
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar